

BIOSYNEX COVID-19 BSS



A rapid test for the qualitative detection of antibodies (IgG and IgM) against SARS-CoV-2 in whole blood, serum, or plasma.

Simple

Can be performed using: whole blood (from venipuncture or fingerstick), serum or plasma

Fast Results in 10 minutes

Complete kit for carrying out 25 tests

The kit can be stored at room temperature or refrigerated (2-30°C)



VIROLOGIE



BIOSYNEX COVID-19 BSS

- COVID-19 is a disease caused by a novel coronavirus (CoV) SARS-CoV-2 also known as 2019-nCoV.
- The most common symptoms of COVID-19 are fever, tiredness, and dry cough. Some people become infected but don't develop any symptoms and don't feel unwell.
- Most estimates of the incubation period for COVID-19 range from 1-14 days.
- The BIOSYNEX COVID-19 BSS (Whole Blood/Serum/Plasma) is a rapid test that utilizes a combination of SARS-COV-2 antigen coated colored particles for the detection of IgG and IgM antibodies to SARS-COV-2 in human whole blood, serum, or plasma.

WHY USE SEROLOGICAL TEST FOR COVID-19?

The antibody-based tests can identify people who were not known to be infected either because they never developed symptoms, or they had symptoms that were never correctly diagnosed. That means the test can identify silent infections, as well as people who were once sick but have recovered.

Lei et al. have shown that antibody positive rates are very low in the first five days after initial onset of symptoms, and then rapidly increased as the disease progressed. Positive rates of viral RNA however remained above 60% in the first 11 days after initial onset of symptoms, and then rapidly decreased (Figure 1).

This demonstrates that serological assay is very important for surveillance and control of the current COVID-19.



Figure 1: Dynamics of the positive rate of viral RNA and antibody of the patients at the different stages of disease⁶.

THE PROCEDURE



MATERIALS INCLUDED

BIOSYNEX COVID-19 BSS

Ref. SW40005

Contains:

- 25 test cassettes
- 1 buffer vial
- 25 droppers/capillary collectors
- Package insert



BIOSYNEX SWISS SA CE Rue de Romont 29 – 31 CH-1700 FRIBOURG Switzerland

Please carefully read the instructions on the package leaflet and/or on outer packaging.

COVID-19

s 🔳

B(0)

с

lgG

lgM

BIBLIOGRAPHY

- 1. World Health Organization (WHO). WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. Beijing: WHO; 9 Jan 2020.
- Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011;81:85-164.
- Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17:181-192.
- 4. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. TrendsMicrobiol 2016;24:490-502.
- 5. Daily risk assessment on CoVid 19. European Centre for Disease Prevention and Control March 8th 2020
- Lei L, Wanbing L, et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. MedRxiv 2020.

BIOSÝNEX

Exclusive distributor: BIOSYNEX SA 22 Boulevard Sébastien Brant Phone : +33 3 88 77 57 52 Fax. : +33 3 59 81 21 74 export@biosynex.com